Back to results
US 8,398,983 B2Granted
Immunogenic composition
AssigneeGlaxosmithkline Biologicals SA
InventorsRalph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
Life of this patent
Estimating the term…
Abstract
The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ug.
Claims31
An immunogenic composition comprising:
- (a) a Haemophilis influenza type b (Hib) saccharide conjugate,
- (b) an N. meningitidis capsular saccharide conjugate derived from a strain selected from the group consisting of serogroups A, B, C, W135 and Y,
- (c) whole cell pertussis, and
- (d) hepatitis B surface antigen,
- wherein the saccharide dose of the Hib saccharide conjugate is less than 5 μg and the saccharide dose of the N. meningitidis capsular saccharide conjugate is less than 5 μg, and wherein the Geometric Mean Concentration (GMC) for whole cell pertussis or hepatitis B achieved with said immunogenic composition is higher than the GMC achieved after immunisation with said immunogenic composition containing a 5 μg saccharide dose of Hib saccharide conjugate and a 5 μg dose of N. meningitidis capsular saccharide conjugate.
2 more elements
Dependencies are inferred from the claim text.